These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2607526)

  • 1. An integrated view of hypertension.
    Kannel WB
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():3-8. PubMed ID: 2607526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of multiple risk factors on the hazard of hypertension.
    Kannel WB
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S53-7. PubMed ID: 11527137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors in hypertension.
    Kannel WB
    J Cardiovasc Pharmacol; 1989; 13 Suppl 1():S4-10. PubMed ID: 2468976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypertension as a function of age].
    Gensini GF; Corradi F
    Ital Heart J; 2000 Jun; 1 Suppl 2():23-31. PubMed ID: 10905125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades.
    Almgren T; Persson B; Wilhelmsen L; Rosengren A; Andersson OK
    J Intern Med; 2005 Jun; 257(6):496-502. PubMed ID: 15910553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
    de Simone G; Olsen MH; Wachtell K; Hille DA; Dahlöf B; Ibsen H; Kjeldsen SE; Lyle PA; Devereux RB
    J Hum Hypertens; 2007 Aug; 21(8):625-32. PubMed ID: 17476291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
    Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiovascular risk factors and prevention in women: similarities and differences].
    Sclavo M
    Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH; Alfayoumi F
    Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study.
    Tsioufis C; Vezali E; Tsiachris D; Dimitriadis K; Taxiarchou E; Chatzis D; Thomopoulos C; Syrseloudis D; Stefanadi E; Mihas C; Katsi V; Papademetriou V; Stefanadis C
    J Hypertens; 2009 Apr; 27(4):744-52. PubMed ID: 19516174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond blood pressure control. Effect of antihypertensive therapy on cardiovascular risk factors.
    Maxwell MH
    Am J Hypertens; 1988 Oct; 1(4 Pt 2):366S-371S. PubMed ID: 3056446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive drug therapy and coronary heart disease risk.
    Schoenberger JA
    J Fam Pract; 1993 Jan; 36(1):70-3, 77-84. PubMed ID: 8419507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective and prospective research on hypertension-related end-organ damage.
    Perloff D
    J Cardiovasc Pharmacol; 1994; 24 Suppl A():S1-5. PubMed ID: 7603071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of electrocardiographic left ventricular hypertrophy to blood pressure, body mass index, serum lipids and blood sugar levels in adult Nigerians.
    Opadijo OG; Omotoso AB; Akande AA
    Afr J Med Med Sci; 2003 Dec; 32(4):395-9. PubMed ID: 15259925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
    J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.